CVS Health faces 340B litigation while leaning into GLP-1 pharmacy growth

Multiple hospital systems have sued CVS Health, accusing the pharmacy and benefits giant and its affiliates of improperly retaining about $250 million in savings tied to the federal 340B drug discount program between 2020 and 2025, a dispute that could test how CVS handles reimbursement flows in the safety-net market.

The complaints, filed in federal courts in New York, Kansas and Michigan, name CVS Health subsidiaries including CaremarkPCS, Caremark LLC, CVS Specialty and Wellpartner, according to the allegations reported by Fierce Healthcare. The plaintiffs include hospitals affiliated with Mount Sinai Health System, the University of Kansas Health System, and the University of Michigan Health, and they say the arrangements were designed to pass along “340B Remittance” amounts but instead were manipulated to retain more of the revenue inside the CVS network.

340B is a federal program that requires drug manufacturers to discount outpatient medications for safety-net providers, and it is widely used by hospitals to fund patient care for lower-income communities. In the CVS case, the plaintiffs describe what they characterize as a coordinated, post-sale pricing process: Wellpartner allegedly flags which claims are eligible for 340B, and the related CVS entities then negotiate reduced rates among themselves while keeping the difference between what outside insurers paid and what the hospitals ultimately received.

Fierce Healthcare reported that the lawsuits say the practice is ongoing and that the hospitals’ damages estimate reflects an internal investigation using a subset of claims and remittance data. The plaintiffs are asking courts to declare breach of contract, order full accounting, and require the defendants to remit amounts they claim were retained, while a CVS spokesperson told the outlet the company does not comment on matters pending in litigation.

At the same time that CVS is defending itself in the courts, its pharmacy benefits arm is marketing a bullish view of GLP-1 growth. In a 2026 GLP-1 outlook report from CVS Caremark, the company projects that weight-management GLP-1 use will grow about 25% in 2026, citing continued demand and the scale of obesity and overweight among U.S. adults.

That report also points to an evolving drug mix, including the arrival of new oral GLP-1 options. It says oral Wegovy is available and that Lilly’s orforglipron is expected mid-2026, which the company frames as expanding choices for patients beyond injectables. CVS Caremark’s strategy for managing the category includes benefit-design tools and utilization-management approaches intended to balance access with affordability, such as a weight-management-focused copay tier described as up to $200 per month and programs that pair GLP-1 therapy with structured lifestyle support.

The juxtaposition highlights the same core business tension across CVS’s segments: how it earns money when prescription reimbursement rules and pricing mechanics shift. CVS’s most recent earnings release emphasized momentum going into 2026 for Caremark, without providing GLP-1-specific financial guidance, while GLP-1 is addressed in the separate Caremark insights report as an area requiring planning around spend and utilization.

Still, important details are not settled. The 340B matter described by Fierce Healthcare reflects allegations, and no court findings were reported in the coverage. In addition, the GLP-1 outlook is presented as an insights report aimed at customers, not as audited forecasts for company earnings, and CVS did not publicly connect that GLP-1 program messaging to any quantified financial impact in the sources reviewed. What can be watched next is whether the litigation schedules accelerate toward remedies like discovery into remittance calculations, and whether CVS’s own customer-facing tools and pricing arrangements around GLP-1 change as utilization grows.